NCT03898219|Completed
Loading search results
Sponsor study identifier
observational
37
1 country
1
Study Start
January 1, 2015
Actual (reported)Primary Completion
April 6, 2016
Actual (reported)Study Completion
April 6, 2016
Actual (reported)To our knowledge, few cases of relapse in adulthood are described in the literature except in patients with sickle cell disease and the epidemiological, clinical, laboratory, radiological features and the management of osteomyelitis relapsing in adulthood are not described. The aim of this retrospective multicentric cohort study : in France is to describe the epidemiological, clinical, laboratory, and radiological features and the management of adult patients who experienced a relapse between 2003-2015 of an acute hematogenous osteomyelitis acquired in the childhood (description of characterization of the period between the first episode of osteomyelitis and the second episode, description of signs of relapse and description of treatments used in the relapse). The data are analysed with non-comparative descriptive statistics.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 6, 2016
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2015
Actual (reported)April 6, 2016
Actual (reported)April 6, 2016
Actual (reported)June 19, 2017
Actual (reported)April 1, 2019
Actual (reported)Rate of patients having an osteomyelitis
Description of the population
Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
rate of bacteria responsible for infection
Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
rate of management with surgery
Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Rate of Treatment Failure
Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Adult patients (≥ 18 years) who presented a relapse between 2003-2015 of a hematogenous osteomyelitis acquired in childhood.
Hospices Civils de Lyon - Hopital de la Croix Rousse
Lyon, 69004, France
37 participants (actual enrollment reported by the registry).
First Submitted
June 19, 2017
First Posted
April 1, 2019
Study Start
January 1, 2015
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
April 6, 2016
Actual (reported)Study Completion
April 6, 2016
Actual (reported)Last Updated
April 1, 2019
Record last verified: 2019-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: